Equities

Twist Bioscience Corp

Twist Bioscience Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)41.21
  • Today's Change9.20 / 28.74%
  • Shares traded4.46m
  • 1 Year change+236.13%
  • Beta1.7369
Data delayed at least 15 minutes, as of May 03 2024 21:15 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.

  • Revenue in USD (TTM)277.49m
  • Net income in USD-192.14m
  • Incorporated2013
  • Employees919.00
  • Location
    Twist Bioscience Corp681 Gateway Blvd.SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (408) 410-0105
  • Fax+1 (302) 531-3150
  • Websitehttps://www.twistbioscience.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arvinas Inc78.50m-367.30m2.24bn445.00--3.38--28.56-6.62-6.621.459.710.061--157.00176,404.50-28.35-22.01-36.10-26.47-----464.71-316.55----0.0012---40.2640.53-30.02--0.4852--
Maravai Lifesciences Holdings Inc288.95m-119.03m2.26bn650.00--5.41--7.82-0.901-0.9012.191.660.15333.152.99444,530.80-7.3412.67-9.7515.4648.5274.79-47.8937.327.41-0.35660.41340.00-67.2818.47-154.05--78.56--
Intellia Therapeutics Inc36.28m-481.19m2.27bn526.00--2.09--62.53-5.42-5.420.410611.290.0257--1.8068,963.88-34.11-31.34-37.31-34.53-----1,326.51-654.71----0.00---30.403.57-1.48--17.08--
Dyne Therapeutics Inc0.00-257.40m2.28bn143.00--4.75-----3.97-3.970.005.490.00----0.00-63.48-52.81-67.12-57.45------------0.00-------40.36--40.32--
Kymera Therapeutics Inc79.41m-154.59m2.29bn186.00--3.23--28.90-2.50-2.501.2911.590.1072--29.69424,668.40-20.86-23.03-22.67-27.64-----194.67-207.82----0.0032--67.84--5.07--91.01--
Guardant Health Inc563.95m-479.45m2.30bn1.78k--14.47--4.08-4.28-4.285.041.300.33214.006.06317,002.80-28.23-22.26-31.99-24.5959.7464.62-85.02-97.076.24-12.040.8778--25.4544.1426.76--0.2786--
Geron Corp237.00k-184.13m2.31bn141.00--8.64--9,732.34-0.3246-0.32460.00040.4550.0008--0.09881,680.85-62.99-51.32-92.09-64.90-----77,690.72-19,949.13----0.2484---60.23-25.97-29.76--120.29--
Sana Biotechnology Inc0.00-283.26m2.31bn328.00--7.18-----1.46-1.460.001.450.00----0.00-40.81-38.99-46.74-42.70------------0.00-------5.11--112.71--
Vericel Corp197.52m-3.18m2.31bn314.00--10.121,476.7311.72-0.0684-0.06844.154.720.63044.263.77629,031.90-1.02-3.07-1.17-3.5068.6467.87-1.61-4.494.21--0.0004--20.1716.8080.96--59.35--
Vera Therapeutics Inc0.00-95.99m2.37bn51.00--18.99-----2.28-2.280.002.290.00----0.00-62.54---74.10--------------0.3291-------7.79------
Twist Bioscience Corp277.49m-192.14m2.38bn919.00--4.28--8.59-3.35-3.354.839.630.35654.877.04301,943.40-24.68-30.50-27.12-33.8438.2936.02-69.24-113.335.06--0.00--20.4157.336.08--49.76--
CG Oncology Inc204.00k-67.80m2.42bn61.00------11,847.53-1.07-1.070.00322.91------3,344.26-------------23,826.96------0.002--6.81---54.83------
Hims & Hers Health Inc872.00m-23.55m2.42bn1.05k--6.99--2.77-0.1131-0.11314.171.612.167.13195.17833,652.00-5.83---7.02--81.99---2.70--2.74--0.00--65.49--64.15------
Denali Therapeutics Inc330.53m-145.22m2.44bn445.00--2.30--7.39-1.09-1.092.397.450.2529----742,766.30-11.11-14.98-13.37-17.71-----43.94-104.50----0.00--204.7420.6755.45--30.70--
TG Therapeutics Inc289.33m41.20m2.50bn264.0073.43--48.038.640.22050.22051.97--------1,095,962.00---62.87---80.0693.53--14.24-405.03--4.01----8,290.02333.86106.39------
Avidity Biosciences Inc9.56m-212.22m2.53bn253.00--4.19--264.57-2.90-2.900.1316.320.0151----37,786.56-33.49-31.61-37.40-34.45-----2,219.88-1,540.50----0.00--3.6490.71-21.97--143.89--
Data as of May 03 2024. Currency figures normalised to Twist Bioscience Corp's reporting currency: US Dollar USD

Institutional shareholders

67.71%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 31 Mar 20246.94m12.01%
The Vanguard Group, Inc.as of 31 Dec 20235.38m9.30%
BlackRock Fund Advisorsas of 31 Dec 20234.70m8.13%
Artisan Partners LPas of 31 Dec 20233.72m6.44%
Nikko Asset Management Americas, Inc.as of 31 Dec 20233.58m6.20%
William Blair Investment Management LLCas of 31 Dec 20233.57m6.18%
Nikko Asset Management Co., Ltd.as of 31 Mar 20243.55m6.14%
SSgA Funds Management, Inc.as of 31 Dec 20233.36m5.82%
JPMorgan Asset Management (UK) Ltd.as of 31 Dec 20232.22m3.83%
JPMorgan Investment Management, Inc.as of 31 Dec 20232.12m3.66%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.